Related Experiment Videos
Paraneoplastic endocrine syndromes: a review
1Department of Pathology, The Rhode Island Hospital and Brown University, Providence, RI, USA. rdelellis@lifespan.org
Endocrine Pathology
|January 24, 2004
Summary
Paraneoplastic endocrine syndromes involve hormone overproduction by tumors, often peptide hormones. Genetic and epigenetic changes likely drive these complex hormonal imbalances.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Paraneoplastic endocrine syndromes result from abnormal hormone production by neoplasms.
- These syndromes encompass diverse symptoms linked to malignant or benign tumors.
- Peptide hormone production is a common feature, sometimes with autocrine effects.
Purpose of the Study:
- To review the spectrum and underlying mechanisms of paraneoplastic endocrine syndromes.
- To highlight hypercalcemia as a frequent manifestation.
- To explore the molecular basis, including genetic and epigenetic factors.
Main Methods:
- Literature review of paraneoplastic endocrine syndromes.
- Discussion of hormone production by neoplasms.
- Analysis of molecular mechanisms, including genetic mutations and epigenetic alterations.
Main Results:
- Hypercalcemia is the most common paraneoplastic endocrine syndrome, often involving parathyroid hormone-related protein (PTHrP).
- Other syndromes are linked to hormones like insulin-like growth factor and fibroblast growth factor 23.
- Molecular mechanisms are complex and not fully understood.
Conclusions:
- Paraneoplastic endocrine syndromes arise from "ectopic" hormone production by tumors.
- Both genetic mutations and epigenetic events, such as methylation, contribute to syndrome development.
- A combination of genetic and epigenetic factors likely underlies these syndromes.